Press Releases SeaStar Medical Holding Corporation

Equities

ICU

US81256L1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.3714 ^USD	+1.42%		-0.51%	-16.11%

May. 14	SeaStar Medical Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility	May. 22	AQ
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update	May. 14	AQ
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure	Apr. 30	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU	Apr. 28	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU	Apr. 20	PR
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update	Apr. 17	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU	Apr. 12	PR
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference	Apr. 11	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU	Apr. 04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU	Mar. 28	PR
SeaStar Medical : Non-Reliance on Previously Issued Financial Report - Form 8-K	Mar. 27	PU
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17	Mar. 27	AQ
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients	Mar. 12	AQ
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024	Mar. 11	AQ
SeaStar Medical : Investor Presentation March	Mar. 01	PU
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure	Feb. 27	AQ
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury	Feb. 22	AQ
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology	Feb. 01	AQ
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market	Jan. 26	AQ
SeaStar Medical Appoints David A. Green as Chief Financial Officer	Jan. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SeaStar Medical Holding Corporation

Equities

ICU

US81256L1044

Press Releases

Filters